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Abstract
Background—It is unclear whether gender and racial/ethnic gaps in the use of and patient 
adherence to β-blockers, angiotensin-converting-enzyme inhibitors (ACEIs)/angiotensin receptor 
blockers (ARBs), and HMG-CoA reductase inhibitors (statins) post-acute myocardial infarction 
(AMI) have persisted following establishment of the Medicare Part D prescription program.
Methods and Results—This retrospective cohort study used 2007-2009 Medicare service 
claims among Medicare beneficiaries ≥ 65 years who were alive 30 days after an index AMI 
hospitalization in 2008. Multivariable logistic regression models examined racial/ethnic (white, 
black, Hispanic, Asian, and Other) and gender differences in the use of these therapies in the 30 
days post-discharge and patient adherence at 12-months post-discharge, adjusting for patient 
baseline sociodemographic and clinical characteristics. Out of 85,017 individuals, 55%, 76%, and 
61% used ACEIs/ARBs, β-blockers, and statins within 30 days post-discharge, respectively. No 
marked differences in use were found by race/ethnicity but women were less likely to use ACEI/
ARBs and β-blockers compared with men. However, at 12-months post-discharge compared with 
white men, black and Hispanic women had the lowest likelihood (approximately 30-36% lower, p 
<0.05) of being adherent, followed by white, Asian, and other women and black and Hispanic men 
(approximately 9-27% lower, p <0.05). No significant difference was shown between Asian/other 
men and white men.
Conclusions—While minorities were initially no less likely to use the therapies post-AMI 
discharge compared with white patients, black and Hispanic patients had significantly lower 
adherence over 12 months. Strategies to address gender and racial/ethnic gaps in the elderly are 
needed.
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Introduction
Hospitalizations and mortality in acute myocardial infarction (AMI) have declined 
considerably in the general population in the past 4 decades due to improvements in AMI 
care and use of evidence-based prevention therapies.1-4 However, racial and ethnic 
disparities in outcomes persist, as the reduction of these outcomes in racial and ethnic 
minorities is much smaller with these groups continuing to experience an excessive burden 
of coronary artery disease.1-4 Recent studies have also shown that women are at higher risk 
of mortality after AMI than men.5-8 Differences in gender and racial/ethnic outcomes may 
be due in part to gender and racial differences in the aggressive use and timely initiation of 
medical treatments in the earlier management of AMI during hospital admission5-7, 9-12
Moreover, the benefit of the evidence-based preventive therapies not only relies on initiation 
but also on long-term adherence to therapies.13-15 Clinical guidelines support the long-term 
use of evidence-based pharmacologic therapies following AMI for secondary prevention, 
including a β-blocker, a lipid lowering agent, an angiotensin converting enzyme inhibitor 
(ACEI) or angiotensin receptor blocker (ARB), and low-dose aspirin.16, 17 Nonetheless, both 
initial use and long-term adherence following AMI have been shown to be alarmingly low in 
general. Some patients never fill their first prescription after discharge.18 One year after 
hospital discharge, approximately 50% of Medicare patients, prior to implementation of 
Medicare Part D, have been shown to be non-adherent to statins, β-blockers, and ACEI/ARB 
treatments.19, 20 If there are significant differential use and adherences to the preventive 
therapies, these differences may also contribute considerably to the racial/ethnic and gender 
disparities in health outcomes after AMI.
Lack of pharmacy benefit and low quality care services may contribute to racial/ethnic 
differences in using preventive therapies.21-23 It is unclear whether gender and racial/ethnic 
gaps still exist in the use of and patient adherence to evidence-based therapies for secondary 
prevention post-AMI compared with findings prior to the Medicare Part D program for 
pharmacy benefits and years after implementation of the Get With The Guidelines (GWTG) 
program.24 This is particularly important in the elderly since the prevalence of AMI is 
highest in this population. Therefore, the aim of our study was to assess whether there were 
gender and racial/ethnic gaps in the use of and patient adherence to evidence-based 
preventive therapy in a large national cohort of elderly Medicare Part D beneficiaries 
following AMI in 2008. In addition, we explored whether follow-up with a cardiologist or 
primary care physician and the total patient out-pocket costs for the 3 therapies post-AMI 
discharge affects the association between gender and race/ethnicity and adherence to the 
therapies.
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All Medicare beneficiaries satisfying the following criteria were included in the cohort: 1) ≥ 
65 years of age; 2) continuous enrollment for at least 12 months before and after the index 
AMI hospitalization in the Medicare fee-for-service and prescription Part D benefits; 3) 
hospitalization for the index AMI between 1/1/2008 and 12/31/2008 and surviving at least 
30 days post-discharge; and 4) discharge to home or to skilled-nursing and long-term care 
facilities and had prescription claims within 30 days after discharge. A 30-day post-
discharge window was chosen to ensure that the prescription fills were most likely related to 
the AMI event itself.18
The Center for Medicare and Medicaid Services (CMS) Medicare Chronic Condition Data 
Warehouse (CCW) enrollment summary, inpatient, outpatient, skilled nursing facility, 
physician office visits, and prescription Part D event service claims files were data sources 
for this study. To obtain the index AMI hospitalization, individuals were identified if they 
had an international classification of disease (ICD)-9 code of 410.x1 in either the primary or 
secondary discharge diagnosis field in the Medicare inpatient claims. Specifically, each 
patient's first instance of AMI hospitalization within the study period was defined as the 
index AMI hospitalization. The study was approved by the Institutional Review Board of the 
University of North Carolina at Chapel Hill.
Race/Ethnicity and Gender Identification
Due to historical issues in how race/ethnicity has been captured in CMS enrollment file, the 
accuracy of race/ethnicity for non-black minorities has been low, and many non-black 
minorities have been misclassified into the ‘other’ category in the CMS enrollment file.25-28 
A 2-step approach was implemented to identify patient race/ethnicity to address this 
issue.25, 28, 29 Patient race/ethnicity was first classified using the race/ethnicity status in the 
Medicare enrollment files. If the patient's race/ethnicity was classified as ‘Unknown’ or 
‘Other’ in the CMS enrollment file, they were then reclassified to either ‘white’, ‘black’, 
‘Hispanic’, ‘Asian’, or “Other” based on the race/ethnicity status if defined by the Research 
Triangle Institute (RTI) race/ethnicity first and last name algorithm variable in the Medicare 
files, which has been shown to increase accuracy of identification.25, 28, 29 This method 
increases sensitivity of race/ethnicity categorization from 29.5 to 76.6% for Hispanic and 
from 54.7 to 79.2% for Asian and Pacific Islander beneficiaries, with no loss of specificity, 
and Kappa coefficients up to 0.80 compared to self-reported race/ethnicity.25, 28
Patient gender was identified by the CMS enrollment file. After gender identification, 10 
race/ethnic and gender groupings were created (i.e., white men, white women, black men).
Measure of Preventive Therapy Use after AMI
Preventive therapy use was defined as filling a prescription within 30 days after the index 
AMI discharge for any ACEIs/ARB, β-blocker, or statin respectively. If an individual had a 
prescription for a drug within the therapeutic class with a remaining supply greater than 30 
days prior to the index AMI admission and filled a prescription for that therapy within 60 
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days after discharge, that therapy was also classified as therapy use post-AMI. Prescription 
drug use was identified through national drug codes in the Part D prescription event files in 
the CCW.
Measure of Adherence to the Preventive Therapies
Adherence to each preventive therapy was calculated as the proportion of days covered by 
the prescription supply calculated from the prescription refill records in the prescription Part 
D claims in the 12 months post-AMI discharge (or until death if occurring within 12 
months) among patients who had the respective preventive therapy within 30 days after AMI 
discharge.30, 31 The adherence measure was also adjusted for overstock of prescription 
supply in the prescription refills and hospital stays during the study period after AMI 
discharge. Conforming to current literature, a patient was defined as adherent if the patient 
had ≥ 80% of days covered with prescription supply in the study period.15, 30
Baseline Characteristics/Covariates
Patient sociodemographic information was ascertained from the CCW enrollment summary 
files at baseline. These characteristics included age, Census average household income at 
ZIP code residence, status in the Medicare Part D benefit plan coverage gap (“doughnut-
hole”) prior to index-AMI admission, and Medicare and Medicaid dual eligibility status. The 
“doughnut-hole” refers to the coverage gap between the initial coverage limit and the 
catastrophic-coverage threshold in the Medicare Part D program, whereby the beneficiary's 
cost-sharing percentage is higher in the “doughnut-hole”. Patient discharge location (e.g., 
home versus skilled nursing facility or other care settings) and geographic region defined by 
US Census regions were also measured.
Levels of comorbidities were measured using the Charlson comorbidity index (CCI) in the 
index year using the CCW claims files in the 12-month baseline period prior to index AMI 
admission.32 Other clinical characteristics measured were diagnosis of cardiovascular 
disease and other related risk factors in the 12-month baseline period (including AMI, 
coronary artery bypass surgery [CABG], stent/percutaneous transluminal coronary 
angioplasty [PTCA], stroke/transient ischemic attack, unstable angina, ischemic heart 
disease, heart failure, atrial fibrillation, peripheral vascular disease, hypertension, diabetes, 
and hyperlipidemia), baseline potential contraindications or intolerant conditions to the 
preventive therapies (chronic kidney disease [CKD], chronic obstructive pulmonary disease 
[COPD], asthma, liver disease, angioedema, hyperkalemia, hypotension, sinus bradycardia, 
heart block, and rhabdomyolysis/other myopathy), prescriptions of β-blockers, ACEIs/
ARBs, and statins in the 6 months prior to the index AMI, AMI type (subendocardial or 
transmural infarction), procedures (CABG, stent/PTCA, cardiac catheterization, infusion of 
thrombolytic, infusion of platelet inhibitors) and complications (heart failure, cardiogenic 
shock, acute renal failure, hypotension, cardiac dysrhythmias) during the index AMI 
hospitalization, and total intensive care unit (ICU) and inpatient stays for the index AMI. 
Those characteristics were measured based on the standardized algorithms in the CCW33 
and other published algorithms.32, 34
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Follow-up with a cardiologist or primary care physician was measured by whether patient 
had service(s) from a cardiologist or primary care physician within 30 days after AMI 
discharge in outpatient and physician office visit claims files. The patient's total out-of-
pocket costs ($0, $1-$10, $11-$50, >$50) for the 3 therapies within 30 days post-discharge 
were calculated using prescription files.
Statistical Analysis
The distribution of patient sociodemographic and clinical characteristics among those who 
had the 3 preventive therapies post-AMI discharge was described. Multivariable logistic 
regression models were applied to examine gender and racial/ethnic differences in the initial 
use and patient adherence of the 3 preventive therapies at 12-months post-index AMI 
hospitalization, respectively. The multivariable models assessed the associations (odds ratio) 
between each racial/ethnic and gender group versus white men as the reference and the use 
and adherence to preventive therapy, adjusting for all measured patient baseline 
sociodemographic and clinical characteristics. The impacts of follow-up with cardiologist/
primary care physician and total out-of-pocket costs for the therapies on the gender and 
racial/ethnic gaps in adherence to the therapies were assessed by additionally adjusting for 
the 3 variables in the models.
Statistical significance was determined at a two-sided alpha < 0.05 level. All analyses were 
conducted using SAS 9.2 (Cary, NC).
Results
There were 85,017 individuals included in the final cohort. The distributions of patient 
sociodemographic and clinical characteristics among the 3 drug therapies (ACEIs/ARBs, β-
blockers, statins) are displayed in Table 1. Of the 85,017 individuals, 47,124 (55%) used 
ACEIs/ARBs, 64,939 (76%) used β-blockers, and 52,185 (61%) used statins within 30 days 
post-AMI hospitalization. Within the race/ethnicity and gender groups, no marked 
differences occurred between race/ethnicity and gender groups between users and non-users.
The distribution of medication use by patient race/ethnicity and gender groups to each 
therapy is displayed in Table 2. The results from multivariable logistic regression models for 
therapy use within the first 30 days post-AMI are presented in Table 3, including 
adjustments for all the baseline characteristics listed in Table 1. A full list of the odds ratios 
(ORs) associated with the use of therapy is presented in Supplemental Table 1. Compared to 
white men, with a few exceptions, there were no significant differences in preventive 
therapy use across race/ethnicity and gender groups. Specifically, white women had a 9% 
lower likelihood of using ACEI/ARB therapy (OR=0.91, 95% CI: 0.88-0.94) and 7% lower 
likelihood of using β-blocker therapy (OR=0.93, 95% CI: 0.90-0.97). Black women had a 
15% lower likelihood of using β-blocker therapy (OR=0.85, 95% CI: 0.77-0.94). 
Conversely, Hispanic women had a 20% greater likelihood of using ACEI/ARB therapy 
(OR=1.20, 95% CI: 1.05-1.37), and Asian women had a 20% greater likelihood of using 
statin therapy (OR=1.20, 95% CI: 1.02-1.41). Sensitivity analysis by 1st or 2nd discharge 
diagnosis of AMI for the index AMI admission yielded consistent results (Supplemental 
Table 2).
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Among all those receiving respective therapies, 63% were adherent to ACEIs/ARBs, 66% 
were adherent to β-blockers, and 66% were adherent to statins over 12 months following 
index AMI discharge. The distribution of adherence by patient race/ethnicity and gender 
categories to each therapy is displayed in Table 4. The distribution of medication adherence 
as a continuous variable is displayed in Supplemental Table 3. The percentage of patients 
who were adherent to the therapies ranged from 54% of black women adherent to ACEIs/
ARBs and 72% of Asian men adherent to statins. Within race/ethnicity classes, a lower 
percentage of women were adherent to the therapies.
Table 5 presents the adjusted associations between patient race/ethnicity and gender and 12-
month adherence for each therapy in the 30 days following discharge, including adjustments 
for all baseline characteristics listed in Table 1. For the 12-month adherence to ACEIs/ARBs 
post-AMI discharge, black women compared to white men had the lowest likelihood (30% 
lower) of being adherent (OR=0.70, 95% CI: 0.62-0.78). White women and black men had 
about a 10% lower likelihood of being adherent compared to white men. No significant 
difference was found between Asians or others versus white men. In β-blocker use, black 
and Hispanic women again had the lowest likelihood of being adherent (36% and 30% 
lower, respectively) compared to white men. Asian/other women and black/Hispanic men 
had a 17% to 26% lower likelihood of being adherent while white women had a 10% lower 
likelihood of being adherent compared to white men. No significant difference was found 
between Asian/other men versus white men. Black and Hispanic men and black, Hispanic 
and other women had an approximately 30% lower likelihood of being adherent to statins 
compared to white men. Comparatively, white women had a 5% greater likelihood of being 
adherent compared with white men to statins. No significant difference was found between 
all other groups and white men. A full list of adjusted ORs of covariates (patient baseline 
characteristics) is available in Supplemental Table 4. For example, higher annual income 
and use of the preventive therapies prior to hospitalization were associated with higher 
adherence.
Additionally adjusting for follow-up with a cardiologist, a primary care physician, and 
patient out-of-pocket medication costs for the 3 therapies did not affect the associations 
between gender and racial/ethnic and groups and adherence to the therapies (Supplemental 
Table 5).
Discussion
In our study of 85,017 Medicare Part D beneficiaries surviving AMI in 2008, 55% received 
an ACEI/ARB, 76% received a β-blocker, and 61% received a statin within 30 days after 
hospital discharge. Similar rates of preventive therapy initiation post-AMI occurred across 
racial/ethnic and gender groups, though women were slightly less likely to initiate ACEI/
ARBs and β-blockers compared with their male counterparts. However, among patients who 
received preventive therapy within 30 days of discharge, 63% were adherent to ACEIs/
ARBs, 66% were adherent to beta-blockers, and 66% were adherent to statins at 12 months 
post-discharge. Black and Hispanic patients had the lowest likelihood of adherence to β-
blockers and statins compared with white men regardless of gender. Black patients also had 
the lowest likelihood of adherence to ACEIs/ARBs. Differences in medication adherence 
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did not extend to Asian patients, with the exception of lower Asian women's adherence to β-
blockers. This study also showed that women, particularly black and Hispanic, resoundingly 
had decreased adherence across the therapy classes regardless of race/ethnicity, with the 
exception of white women to statins, despite similar rates of use within 30 days post-
discharge.
This study demonstrates that despite remarkable progress in eliminating gaps in initiation of 
treatment by elderly racial/ethnic and gender groups following acute AMI, considerable 
differences in continuing care, such as medication adherence, still strongly persist. The 
similar rates of use of the preventive therapies within 30 days post-discharge in 2008 
suggests that racial/ethnic gaps in the initiation of preventive drug use after AMI have been 
considerably mitigated after the establishment of the Part D prescription program and years 
following implementation of the GWTG program.24 These findings are consistent with a 
recent study examining racial differences in AMI care in 443 hospitals in the GWTG – 
Coronary Artery Disease program from 2002 to 2007.11 In this study, the gap between 
minorities (black and Hispanic) and white in prescribing of lipid lowering therapy, ACEIs/
ARBs and β-blockers at discharge improved over time and was no longer significant after 
2004.11 Our study further highlights that no significant racial/ethnic gaps exist in filling 
discharge prescriptions for the preventive therapies post-AMI.
However, our study demonstrates that much more still needs to be done to address gaps in 
continuity of receiving life and cost-saving preventive therapies for older adults of racial/
ethnic minorities and women, which to our knowledge has not been elucidated in any other 
recent research. Our study still found a considerable gap between black and Hispanic 
patients compared to white patients in long-term adherence to preventive therapies even 
after adjustment for patient baseline sociodemographic and clinical characteristics. This 
unexplained gap may suggest racial/ethnic differences in the quality of care issues related to 
patient adherence. Notably, this study found that disparities were not equally distributed 
across all minority groups. Asians tended to have better adherence than other minority 
groups. Previous research has indicated that underlying heterogeneity in Asian populations 
in medication use may exist; it is unclear whether disparities in medication adherence exist 
within various Asian racial/ethnic subgroups.35
Qualitatively compared with studies assessing adherence to secondary preventive therapies 
following AMI prior to implementation of the Medicare Part D program20, 36, our study 
suggests that the percentage of patients adherent to these medications has increased slightly. 
However, the association between race/ethnic and gender gaps in adherence warrants 
additional consideration. Our findings suggested a fairly strong association of gender with 
medication adherence in that women, particularly black and Hispanic, were considerably 
less likely to be adherent than men post-AMI discharge. Lack of social support, lack of 
community resources, and individual-level characteristics such as cognitive deficiencies, 
may also lead to gaps in medication adherence and may differentially affect women of 
ethnic minorities.37, 38 In addition, this finding may suggest a continued controversy of 
women receiving less aggressive treatment with preventive therapies than men for AMI 
even though the mortality risk after AMI is higher in women.5, 7, 10, 12 Recent studies have 
suggested that women tend to present different AMI symptoms (e.g., less chest pain) than 
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men, and women with less chest pain or discomfort were less likely to receive aggressive 
AMI management and preventive therapies.8, 39 A gender bias in physicians' attitude has 
been suggested in the use of secondary prevention therapies in patients with coronary artery 
disease.40 This gender bias may also have influenced women's adherence.
Further, the differential gaps across the preventive therapies raised an interesting clinical 
question. For example, white women were significantly more adherent to statins but less 
adherent to ACEIs/ARBs and beta-blockers at 12 months post-discharge compared with 
white men. Asian women had comparatively better adherence to statins and ACEIs/ARBs 
than to β-blockers. If therapy use and adherence were influenced in part by physician and 
patient expectations of treatment benefit and risk, the differential therapy use and adherence 
may signal different beliefs on benefit and risk of the therapies post-AMI in specific racial/
ethnic and gender groups. However, the legitimacy of such beliefs needs to be addressed. 
Further research may need to study why patients exhibit stronger preferences towards 
adherence to certain therapy classes but not others following AMI.
Many factors, for example physician follow-up, follow-up lab tests, continuity of care, 
coordination of care, and medication copayment, have been shown to affect patients' 
adherence to cardiovascular preventive therapies.41-43 In our study, adjusting for follow-up 
with cardiologist, primary care physician or total patient out-of-pocket medication costs of 
the 3 preventive therapies did not diminish the gaps in adherence post-AMI, suggesting that 
adherence post-AMI can be complex. A previous study has suggested that black patients 
received care services from lower quality primary care providers than white patients.22 It is 
possible that the quality of the visit may be more influential in the gender and racial-ethnic 
gaps in patient adherence than just a visit itself. Communication between providers and 
patients is also significantly associated with adherence.44, 45 Future studies are needed to 
assess the impact of quality of care on gaps in adherence across gender and racial/ethnic 
groups.
Care services related to patient adherence involve multiple care providers (cardiologists, 
primary care physicians, and pharmacists) across institutional and community settings. 
However, the GWTG program traditionally focuses on the prescribing of evidence-based 
therapies at hospital discharge. Only recently has the GWTG program begun expanding 
efforts to the outpatient setting. Our study finding shows a great need for the uptake of such 
programs focused on medication adherence by healthcare providers serving minorities as 
well. Also, the program may need to emphasize the equal importance of AMI care quality 
measures in both men and women.
Our study has several limitations. First, using prescription refill records may not fully 
represent actual intake of the medication. However, prescription refill records have been 
shown to have good validity, correlation, and similar sensitivity and specificity as other 
adherence measurements, including self-report, pill counts, and electronic records.15, 30, 46 
Use of over-the-counter therapies, such as low-dose aspirin, is not available within Medicare 
Part D prescription data. The accuracy of race/ethnicity identification for non-black 
minorities has been low in the Medicare enrollment file due to historical issues. To address 
this limitation, we applied the race/ethnicity status coded by RTI in a first and last names 
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algorithm to improve the sensitivity of non-black minority categorizations in Medicare 
enrollment data files.25, 28 Despite this improvement, some individuals may still be 
categorized as “other” as the RTI imputations are based on name algorithms. While this 
algorithm may not fully resolve misclassification, it significantly improves the 
classifications in Medicare data.25, 28 The direct impact of racial/ethnic and gender gaps in 
adherence on cardiovascular outcomes were also not examined in this study. However, the 
clinical significance of gender and racial/ethnic gaps in adherence to post-AMI preventive 
therapies is supported by the literature that the lack of medication adherence is associated 
with an increase in adverse outcomes.15, 47 Post-AMI patients with low 1-year adherence to 
statins were shown to have 25% and 12% higher mortality risk compared to patients with 
high and intermediate 1-year adherence. 15 Similar dose-response adherence-mortality 
association was also observed for β-blockers. 15
There are several strengths of this study. This study used a large national cohort from a 
100% sample of Medicare beneficiaries enrolled in fee-for-service and prescription Part D 
programs and survived AMI in 2008. The large sample well represented the general elderly 
population. Most prior studies examining racial/ethnic and gender gaps in the management 
and care for AMI have been focused on the prescribing at discharge and before the 
beginning of the Medicare Part D program.5-7, 9-12 This study assessed prescriptions for 
preventive therapies filled after discharge after the Medicare Part D program was well 
established.
Conclusion
Our study showed no evidence of racial/ethnic/gender differences in the use of β-blockers, 
ACEIs/ARBs, and statins following AMI within 30 days with a few specific exceptions. 
However, minority patients, as compared to white patients, were significantly less adherent 
to the 3 preventive therapies at 12 months post-discharge. Minority women particularly 
black and Hispanic women had largely decreased medication adherence compared to white 
men. Thus, even after the introduction of the Medicare Part D program and years of GWTG 
implementation, gender and racial/ethnic gaps in patient long-term adherence to evidence-
based preventive therapies following AMI appear to still persist. Clinicians, researchers, and 
policy-makers should continue to focus attention on eliminating differences in care 
following AMI, even months after the initial event.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Distribution of use of ACEIs/ARBs, β-blockers and statins within 30 days post-AMI by 
race/ethnicity and gender






White Men 41,196 56.28 76.41 59.31
White Women 31,130 53.44 77.03 64.02
Black Men 5,050 57.47 74.18 58.63
Black Women 2,431 53.52 72.73 60.92
Hispanic Men 1,382 61.22 76.27 62.08
Hispanic Women 1,076 59.94 78.07 64.59
Asian Men 884 60.07 75.79 63.69
Asian Women 875 58.29 76.23 71.09
Other Men 576 57.47 73.26 63.19
Other Women 417 57.07 76.26 66.43
Abbreviations: AMI, Acute Myocardial Infarction; ACEI, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blocker
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